Review of Systemic Treatment Options for Adult Atopic Dermatitis

J Cutan Med Surg. 2017 Jan/Feb;21(1):31-39. doi: 10.1177/1203475416670364. Epub 2016 Sep 22.

Abstract

Background: Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease resulting from defects in skin barrier and aberrant immune responses. AD significantly affects the quality of life. Not all patients respond to topical therapies, and often systemic therapy is required to control the disease.

Objective: To review the treatment options for adult AD patients including those options for patients who do not respond adequately or have contraindications to oral systemic therapy.

Methods: A working group of clinicians with experience managing AD was convened to review the current literature on treatment options for adult AD patients. This review is based on the best available evidence from a published systematic review and an additional literature search.

Results: Current treatments for AD are reviewed, including options for adult AD patients who do not respond or have contraindications to current systemic therapies. A new approach with targeted therapies is reviewed based on best available evidence.

Conclusion: Many AD patients respond satisfactorily to topical or systemic treatments, but for those patients who do not respond or have contraindications, new biologic agents appear to be promising therapies.

Keywords: IL-13; IL-4; adults; atopic dermatitis; biologics; dupilumab; systemic therapy.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Azathioprine / therapeutic use
  • Biological Products / administration & dosage
  • Biological Products / therapeutic use*
  • Cyclosporine / therapeutic use
  • Dermatitis, Atopic / drug therapy*
  • Humans
  • Quality of Life

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • dupilumab
  • Cyclosporine
  • Azathioprine